"Thanks to new Multiplicom test kits physicians are able to identify all the genetic mutations of a condition at once, and use this information to initiate the right - personalized - treatment.”
Agilent Technologies to Acquire Multiplicom N.V., a Leading European Diagnostics Company with State-of-the-Art Genetic Testing Technology and Products
Agilent Technologies Inc. (NYSE: A) and Multiplicom N.V. announced on 20 December 2016 that they have signed a definitive agreement under which Agilent will acquire Multiplicom, a leading European diagnostics company with state-of-the-art genetic testing technology and products.
Multiplicom, headquartered in Niel, Belgium, develops, manufactures and commercializes molecular-diagnostic solutions, provided as kits, which enable personalized medicine. Specifically, these solutions enable clinical labs to identify the DNA variants that are associated with a genetic disease or predisposition in patients, or that may steer cancer therapy or identify congenital defects early in pregnancy.
“The acquisition of Multiplicom significantly strengthens our presence in the genomics market,” said Herman Verrelst, vice president and general manager of Agilent’s Genomics Division. “Multiplicom’s products and technology help expand our target-enrichment portfolio and enhance our next-generation sequencing workflow capabilities – providing immediate scale in adjacent markets.”
“Multiplicom is excited to be a part of Agilent and for the opportunity to offer our products and technology to a global customer base,” said Dirk Pollet, Multiplicom’s CEO. “We are also immensely grateful to our investors Gimv, PMV, Qbic, RMM, University of Antwerpen and VIB for their unwavering support from Day One.”
Agilent is acquiring Multiplicom for approximately €68 million in cash. The acquisition is expected to be completed by mid-January, subject to local laws and regulations and customary closing conditions. Multiplicom employs about 90 people, all of whom will be offered employment opportunities with Agilent.
About Multiplicom N.V.
Multiplicom N.V. develops, manufactures and commercializes molecular diagnostic solutions, provided as kits, which enable personalized medicine. Founded in 2011 as a spin-off from the University of Antwerp (Belgium) and VIB (Flanders Institute of Biotechnology), Multiplicom achieved CE-IVD certification for the BRCA MASTR Dx assay for breast and ovarian cancer predisposition in 2012. It was the first company in Europe to achieve a BRCA CE-IVD certification and it continues to develop and market quality controlled NGS-based assays. Therefore, it enables clinical laboratories to identify the DNA variants that are associated with a genetic disease or predisposition in patients, or that may steer cancer therapy or to identify congenital defects early in pregnancy. For more information, visit www.multiplicom.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenue of $4.20 billion in fiscal 2016. The company employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.
Q: What was announced?
Multiplicom N.V. and Agilent Technologies have signed an agreement for Multiplicom to join Agilent Technologies, one of the world’s top partners to clinical and diagnostic laboratories.
Q: When will the transaction be completed?
The acquisition is expected to be completed by mid-January, subject to local laws and regulations and customary closing conditions.
Q: What changes can I expect to see immediately?
Until the agreement closes, Multiplicom and Agilent will remain separate companies with each conducting business as usual. The acquisition is expected to close by mid-January – subject to local laws and regulations and customary closing conditions. Formal integration is expected to begin in early March.
Q: Will Multiplicom’s senior management team join Agilent?
Yes, the Multiplicom team is joining the Genomics Division of Agilent’s Diagnostics and Genomics Group (DGG).
Q: Will my Multiplicom point of contact change?
All Multiplicom employees and contractors will be offered opportunities at Agilent. You may expect to continue to work with the same Multiplicom people with whom you have been working.
Q: Will the way I use the Multiplicom products and solutions change?
There are no plans to change the fundamental Multiplicom products and solutions product or strategy at this time. We will work to expand our offerings into other geographies as we move forward under Agilent.
Q: Will our products be rebranded as Agilent?
Yes, a rebranding plan is being developed. Timing and further details are yet to be finalized.
Q: If I have additional questions, what should I do?
For more information, please contact firstname.lastname@example.org.
MORE ABOUT AGILENT
Q: Can you tell me about Agilent?
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give their customers the highest confidence in their solutions.
Q: What does Agilent focus on?
Agilent focuses its expertise on six key markets, where they help their customers achieve their goals. These areas are Pharmaceutical, Diagnostics, Food, Environment and Forensics, Chemical and Energy, and Research.
Q: How will customers benefit from this acquisition?
Once formal integration begins, Multiplicom’s customers will have direct access to Agilent’s broader portfolio of offerings. Together, we have the potential to accelerate new product introductions by leveraging our joint R&D infrastructure and expertise, ultimately benefitting our customers.